ArticlePharmacoEconomics2021
A Net Benefit Approach for the Optimal Allocation of a COVID-19 Vaccine.
Article in PharmacoEconomics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 5 syntheses or guidelines pooled it, 36 citations in OpenAlex.
- Data-driven strategies for model-informed decision-making during the COVID-19 pandemic: a systematic review.BMJ open · 2026Pooled it
- Economic Evaluation of COVID-19 Immunization Strategies: A Systematic Review and Narrative Synthesis.Applied health economics and health policy · 2024Pooled it
- Predictive models for health outcomes due to SARS-CoV-2, including the effect of vaccination: a systematic review.Systematic reviews · 2024Pooled it
- Economic evaluation of COVID-19 vaccination: A systematic review.Journal of global health · 2023Pooled it
- Cost-effectiveness of interventions for the prevention and control of COVID-19: Systematic review of 85 modelling studies.Journal of global health · 2022Pooled it
- An agent-based model of the effects of limited vaccination on novel respiratory infections.Journal of clinical epidemiology · 2026Article
- Article
- A novel comparison framework for epidemiological strategies applied to age-based restrictions versus horizontal lockdowns.Infectious Disease Modelling · 2024Article
- Improving Transparency of Decision Models Through the Application of Decision Analytic Models with Omitted Objects Displayed (DAMWOOD).PharmacoEconomics · 2024Article
- Impact of community mask mandates on SARS-CoV-2 transmission in Ontario after adjustment for differential testing by age and sex.PNAS nexus · 2024Article
- An optimal control model for Covid-19 spread with impacts of vaccination and facemask.Heliyon · 2023Article
- Quantifying the economic gains associated with COVID-19 vaccination in the Canadian population: A cost-benefit analysis.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Relative pandemic severity in Canada and four peer nations during the SARS-CoV-2 pandemic.Canada communicable disease report = Releve des maladies transmissibles au Canada · 2023Article
- Review
- Economic evaluation of COVID-19 rapid antigen screening programs in the workplace.BMC medicine · 2022Article
- Mathematical modeling of COVID-19 in British Columbia: An age-structured model with time-dependent contact rates.Epidemics · 2022Article
- Vaccine and inclusion.Journal of public economic theory · 2022Article
- Models of COVID-19 vaccine prioritisation: a systematic literature search and narrative review.BMC medicine · 2021Review
- Best COVID-19 vaccine allocation strategy using a net-monetary benefit approach?PharmacoEconomics & outcomes news · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
Abstract
objectiveThe objective of this study was to implement a model-based approach to identify the optimal allocation of a coronavirus disease 2019 (COVID-19) vaccine in the province of Alberta, Canada.
methodsWe developed an epidemiologic model to evaluate allocation strategies defined by age and risk target groups, coverage, effectiveness and cost of vaccine. The model simulated hypothetical immunisation scenarios within a dynamic context, capturing concurrent public health strategies and population behavioural changes.
resultsIn a scenario with 80% vaccine effectiveness, 40% population coverage and prioritisation of those over the age of 60 years at high risk of poor outcomes, active cases are reduced by 17% and net monetary benefit increased by $263 million dollars, relative to no vaccine. Concurrent implementation of policies such as school closure and senior contact reductions have similar impacts on incremental net monetary benefit ($352 vs $292 million, respectively) when there is no prioritisation given to any age or risk group. When older age groups are given priority, the relative benefit of school closures is much larger ($214 vs $118 million). Results demonstrate that the rank ordering of different prioritisation options varies by prioritisation criteria, vaccine effectiveness and coverage, and concurrently implemented policies.
conclusionsOur results have three implications: (i) optimal vaccine allocation will depend on the public health policies in place at the time of allocation and the impact of those policies on population behaviour; (ii) outcomes of vaccine allocation policies can be greatly supported with interventions targeting contact reduction in critical sub-populations; and (iii) identification of the optimal strategy depends on which outcomes are prioritised.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.